Literature DB >> 19403853

The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors.

Mark A Smith1, Jennifer L Greene-Naples, Megan A Lyle, Jordan C Iordanou, Jennifer N Felder.   

Abstract

Repeated administration of many addictive drugs leads to a progressive increase in their locomotor effects. This increase in locomotor activity often develops concomitantly with increases in their positive-reinforcing effects, which are believed to contribute to the etiology of substance use disorders. The purpose of this study was to examine changes in sensitivity to the locomotor effects of opioids after their repeated administration and to determine the role of mu and kappa receptors in mediating these effects. Separate groups of rats were treated with opioid receptor agonists and antagonists every other day for 10 days, and changes in locomotor activity were measured. Repeated administration of the mu agonists, morphine and buprenorphine, produced a progressive increase in locomotor activity during the treatment period, and this effect was blocked by coadministration of the opioid antagonist naltrexone. The kappa agonist spiradoline decreased locomotor activity when administered alone and blocked the progressive increase in locomotor activity produced by morphine. The ability of spiradoline to block morphine-induced increases in locomotor activity was itself blocked by pretreatment with the kappa antagonist nor-binaltorphimine. Repeated administration of high doses, but not low or moderate doses, of the mixed mu/kappa agonists butorphanol, nalbuphine, and nalorphine produced a progressive increase in locomotor activity during the treatment period. Doses of butorphanol, nalbuphine, and nalorphine that failed to produce a progressive increase in locomotor activity when administered alone did so when subjects were pretreated with nor-binaltorphimine. These findings suggest that mu and kappa receptors have functionally opposing effects on opioid-mediated locomotor activity and sensitization-related processes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19403853      PMCID: PMC2713083          DOI: 10.1124/jpet.108.150011

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  44 in total

1.  Dopaminergic mechanisms mediating the long-term expression of locomotor sensitization following pre-exposure to morphine or amphetamine.

Authors:  L J Vanderschuren; A N Schoffelmeer; A H Mulder; T J De Vries
Journal:  Psychopharmacology (Berl)       Date:  1999-04       Impact factor: 4.530

2.  The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor.

Authors:  D Morgan; M J Picker
Journal:  Psychopharmacology (Berl)       Date:  1998-11       Impact factor: 4.530

3.  Biphasic effects of a potent enkephalin analogue (D-Met2,Pro5)-enkephalinamide and morphine on locomotor activity in mice.

Authors:  J I Székely; E Miglécz; A Z Rónai
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

4.  Effects of intraventricular morphine and enkephalins on locomotor activity in nondependent, morphine-dependent and postdependent rats.

Authors:  L S Brady; S G Holtzman
Journal:  J Pharmacol Exp Ther       Date:  1981-09       Impact factor: 4.030

5.  Examination of the kappa agonist and antagonist properties of opioids in the rat drug discrimination procedure: influence of training dose and intrinsic efficacy.

Authors:  M.A. Smith; M.J. Picker
Journal:  Behav Pharmacol       Date:  1995-11       Impact factor: 2.293

Review 6.  Nalbuphine.

Authors:  W K Schmidt; S W Tam; G S Shotzberger; D H Smith; R Clark; V G Vernier
Journal:  Drug Alcohol Depend       Date:  1985-02       Impact factor: 4.492

Review 7.  Butorphanol tartrate (stadol): a review.

Authors:  J Vogelsang; S R Hayes
Journal:  J Post Anesth Nurs       Date:  1991-04

8.  The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat.

Authors:  C A Heidbreder; S R Goldberg; T S Shippenberg
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

9.  Tolerance development to the biphasic effects of morphine on locomotor activity and brain acetylcholine in the rat.

Authors:  M R Vasko; E F Domino
Journal:  J Pharmacol Exp Ther       Date:  1978-12       Impact factor: 4.030

10.  Time course of antagonism of morphine antinociception by intracerebroventricularly administered naloxone in the rat.

Authors:  F Porreca; A Cowan; R J Tallarida
Journal:  Eur J Pharmacol       Date:  1981-11-19       Impact factor: 4.432

View more
  9 in total

1.  The effects of repeated opioid administration on locomotor activity: II. Unidirectional cross-sensitization to cocaine.

Authors:  Mark A Smith; Jennifer L Greene-Naples; Jennifer N Felder; Jordan C Iordanou; Megan A Lyle; Katherine L Walker
Journal:  J Pharmacol Exp Ther       Date:  2009-04-29       Impact factor: 4.030

2.  Some determinants of morphine effects on intracranial self-stimulation in rats: dose, pretreatment time, repeated treatment, and rate dependence.

Authors:  Ahmad A Altarifi; Sidney Stevens Negus
Journal:  Behav Pharmacol       Date:  2011-10       Impact factor: 2.293

3.  Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice.

Authors:  Laurence L Miller; Mitchell J Picker; Karl T Schmidt; Linda A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  2011-03-04       Impact factor: 4.530

4.  Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice.

Authors:  Laurence L Miller; Mitchell J Picker; Michael D Umberger; Karl T Schmidt; Linda A Dykstra
Journal:  J Pharmacol Exp Ther       Date:  2012-04-18       Impact factor: 4.030

5.  Effects of buprenorphine, meloxicam, and flunixin meglumine as postoperative analgesia in mice.

Authors:  Jacquelyn T Tubbs; Grace E Kissling; Greg S Travlos; David R Goulding; James A Clark; Angela P King-Herbert; Terry L Blankenship-Paris
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-03       Impact factor: 1.232

6.  Effect of pain management on immunization efficacy in mice.

Authors:  April M Kolstad; Ramona M Rodriguiz; Caroline J Kim; Laura P Hale
Journal:  J Am Assoc Lab Anim Sci       Date:  2012-07       Impact factor: 1.232

7.  The mu/kappa agonist nalbuphine attenuates sensitization to the behavioral effects of cocaine.

Authors:  M A Smith; K T Cole; J C Iordanou; D C Kerns; P C Newsom; G W Peitz; K T Schmidt
Journal:  Pharmacol Biochem Behav       Date:  2013-01-07       Impact factor: 3.533

8.  The γ-aminobutyric acid type B (GABAB) receptor agonist baclofen inhibits morphine sensitization by decreasing the dopamine level in rat nucleus accumbens.

Authors:  Zhenyu Fu; Hongfa Yang; Yuqiang Xiao; Gang Zhao; Haiyan Huang
Journal:  Behav Brain Funct       Date:  2012-07-10       Impact factor: 3.759

9.  Effects of Cebranopadol on Cocaine-induced Hyperactivity and Cocaine Pharmacokinetics in Rats.

Authors:  Huimei Wei; Linyue Shang; Chang-Guo Zhan; Fang Zheng
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.